Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > FDA then Licensing Deal

<< Previous

Bullboard Posts

Next >>

Post by SundayMovieson Jun 07, 2023 1:08pm

209 Views

Post# 35484716

FDA then Licensing Deal

KOL - Basically FDA will change the endpoints and accept PFS.

After FDA accelerated approval news, we have 100% certainty of a deal.

So, yes market should buy the heck out of the stock.

Can you fire the person that choose the Checkpoint inbitior and the stop talking to the collaborator company that suggest this. This will save cash burn a bit.

Also, if there is a reasonable offer. Just take it. Management is not the most competent here.

KOL was quite embarrasing to listen to...

<< Previous

Bullboard Posts

Next >>

How a junior advances one of the largest undeveloped diamond projects